Keytruda meets OS endpoint for second-line esophageal cancer

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab as monotherapy met the primary endpoint of improving overall survival (OS) vs. investigator's choice of chemotherapy in the Phase III

Read the full 285 word article

User Sign In